Exelixis, Inc.
EXELHealthcareNASDAQBiotechnology · Last scanned Oct 26, 2026
Scan Results
Daily timeframePart of the healthcare sector, Exelixis, Inc. (EXEL) is listed under Biotechnology. The $15.99B market capitalization puts EXEL squarely in large-cap range for its industry. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Market Cap
$15.99B
Beta
0.47
P/E (TTM)
20.36
P/E (Fwd)
15.10
EPS (TTM)
$3.17
EPS (Fwd)
$4.27
ROE
44.4%
ROA
24.0%
Cash
$839.4M
Total Debt
$165.9M
Free CF
$739.7M
52W Change
61.4%
Annual Financials
Cash vs Debt
Where EXEL stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, EXEL finished 20.12% above its 150-day moving average ($52.18) and 25.51% above its 200-day moving average ($49.94). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is EXEL overbought or oversold?
At the October 20, 2026 close, EXEL's RSI(14) was 74.0, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $839.4M in cash comfortably exceeding the $165.9M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $739.7M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 44.4% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 24.0% further supports the picture of efficient asset utilization. Revenue has grown from $1.61B (2022) to $2.32B (2025), reflecting a 44% increase over the period.
With a beta below 0.7, Exelixis, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. No single metric tells the full story. Reviewing EXEL's risk profile alongside its fundamentals and technical indicators provides a more complete picture.